Professor Stephen Anderton
Group Head of Translational Biology
Steve founded Aquila in 2011 and, as CSO, built the company to acquisition by Concept Life Sciences in 2017. He is now Group Head of Translational Biology across Concept, combining this with his role as Professor of Therapeutic Immunology at the University of Edinburgh, where he is an investigator at the MRC Centre for Inflammation Research and the Cancer Research UK Edinburgh Centre. Steve is an internationally leading immunologist, with 120+ publications on T cell activation, T cell tolerance, Treg biology and immunotherapy of inflammatory disease and cancer. This expertise enables Aquila’s scientific team to deliver our innovative biology platforms.
VP of Translational Biology
Clare joined Aquila at the point of company creation in 2011, after 13 years working in the global CRO sector (previously Quintiles and Aptuit). Along with company founders and Principal Scientist (Dr Hayley Gooding), Clare has built Aquila into a thriving high growth company that is innovative and responsive to our increasing client requirements. She brings a combination of scientific insight, business acumen and leadership to the Aquila team. Now under the new ownership of Concept Life Sciences (and Spectris) Clare will be instrumental in navigating the team through the transition and beyond.Connect
Dr Louise Welch
Business Development & Marketing Associate
Louise joined Aquila in 2016 in a dual role as our Business Development and Marketing Associate. She has a PhD in immunology from the University of Edinburgh and brings experience of Science Communication and marketing skills to the company. In this role, she has been instrumental in rebranding the company, launching a new website and taking responsibility for the business pipeline. Louise is the first point of contact for Aquila and supports clients through their journey in working with Aquila.Connect